Intravitreal toxicity of doxycycline. A pilot study;Toxicidad retiniana de doxiciclina intravítrea. Estudio piloto

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 82, Issue 4, 2007, Pages 223-228

  Aydin, E ^a,b,c   Kazi, A A ^b   Peyman, Gholam A ^b,e   Esfahani, M R ^b   Munoz Morales A ^b   Kivilcim, M ^b   Caro Magdaleno, M ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c GAZIOSMANPASA UNIVERSITY   (Turkey)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e NONE   (United States)

Author keywords

Doxycycline; Endophthalmitis; Intravitreal injection; Retinal toxicity

Indexed keywords

ANTIINFECTIVE AGENT; DOXYCYCLINE;

ACOUSTIC MICROSCOPY; ANIMAL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; INJECTION; OPHTHALMOSCOPY; PATHOLOGY; PILOT STUDY; RABBIT; RETINA; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG EVALUATION, PRECLINICAL; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; INJECTIONS; MICROSCOPY, ACOUSTIC; OPHTHALMOSCOPY; PILOT PROJECTS; RABBITS; RETINA; VITREOUS BODY;

EID: 34547662163     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Javitt JC, Street DA, Tielsch JM, Wang Q, Kolb MM, Schien O, et al. National outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Cataract Patient Outcomes Research Team. Ophthalmology 1994; 101: 100-106.
2. Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology 1998; 105: 2171-2177.
3. Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levofloxacin in human eyes. Curr Eye Res 2002; 24: 403-406.
4. Peyman GA. Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections. Surv Ophthalmol 1977; 21: 339-346.
5. Flynn HW Jr, Pulido JS, Pflugfelder SC, Davis JL, Culbertson WW, Roussel TJ, et al. Endophthalmitis therapy: changing antibiotic sensitivity patterns and current therapeutic recommendations. Arch Ophthalmol 1991; 109: 175-176.
6. Thomas T, Galiani D, Brod RD. Gentamicin and other antibiotic toxicity. Ophthalmol Clin North Am 2001; 14: 611-624.
7. Homer P, Peyman GA, Koziol J, Sanders D. Intravitreal injection of vancomycin in experimental staphylococcal endophthalmitis. Acta Ophthalmol (Copenh) 1975; 53: 311-320.
8. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
9. Sepala H, Al-Juhaish M, Jarvinen H, Laitinen R, Huovinen P. Effect of prophylactic antibiotics on antimicrobial resistanse of viridans streptococci in the normal flora of cataract surgery patients. J Cataract Refract Surg 2004; 30: 307-315.
10. Jones RN, Sader HS, Fritsche TR. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Diagn Microbiol Infect Dis 2004; 49: 147-149.
11. Forslin L, Danielson D, Kjellander J, Falk V. Antibiotic treatment of acute salpingitis. A study of plasma concentrations of two tetracyclines (doxycycline and lymecycline). Acta Obstet Gynecol Scand 1982; 61: 59-64.
12. Nakata K, Maeda H, Fujii A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36: 188-190.
13. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995; 113: 1257-1265.
14. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs 2001; 61: 747-761.
15. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina 2006; 26: 187-190.
16. Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea 1998; 17: 282-287.
17. O'Day DM, Jones DB, Patrinely J, Elliott JH. Staphylococcus epidermidis endophthalmitis. Visual outcome following noninvasive therapy. Ophthalmology 1982; 89: 354-360.
18. Crossley K, Loesch D, Landesman B, Mead K, Chern M, Strate R. An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies. J Infect Dis 1979; 139: 273-279.
19. Peacock JE Jr, Marsik FJ, Wenzel RP. Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Ann Intern Med 1980; 93: 526-532.
20. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-1523.
21. Aldridge KE, Janney A, Sanders CV. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations. Antimicrob Agents Chemother 1985; 28: 634-638.
22. Cunha BA. Doxycycline for community-acquired pneumonia [letter]. Clin Infect Dis 2003; 37: 870.
23. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect 2000; 6: 270-273.
24. Ross JE, Jones RN. Quality Control Working Group. MIC quality control guidelines for doxycycline when testing gram-positive control strains by the reference methods. Diagn Microbiol Infect Dis 2004; 50: 295-297.
25. Wallace I, Krupin T, Stone RA, Moolchandani J. The ocular hypotensive effects of demeclocycline, tetraciclyne and other tetraciclyne derivatives. Invest Ophthalmol Vis Sci 1989; 30: 1594-1598.
26. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89: 131-136.